c-Met-IN-32
c-Met-IN-32 is an orally active c-Met inhibitor with an IC50 of 18 nM, blocking autophosphorylation and downstream PI3K/AKT and RAS/ERK signaling pathways. c-Met-IN-32 inhibits MER, FYN, and SRC kinases. c-Met-IN-32 induces apoptosis, inhibits migration and invasion, suppresses the proliferation of MET-amplified cancer cells, and exhibits selectivity against non-MET-dependent cancer cell lines. c-Met-IN-32 can be used for research on non-small cell lung cancer.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- 화학식: C35H36F2N4O6
- 분자량:646.68
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
제품 설명
IC50 & Target
[1]|
c-Met 18 nM (IC50) |
PI3K |
Akt |
Ras |
ERK |
Fyn |
MER |
Src |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| EBC-1 | IC50 |
0.12 μM
|
Antiproliferative activity against human MET-amplified EBC-1 NSCLC cells assessed as viability reduction incubated 72 hrs by CCK-8 assay.
Antiproliferative activity against human MET-amplified EBC-1 NSCLC cells assessed as viability reduction incubated 72 hrs by CCK-8 assay.
|
42748863 |
| A549 | IC50 |
2.5 μM
|
Antiproliferative activity against human A549 non-MET-addicted cancer cells assessed as viability reduction incubated 72 hrs by CCK-8 assay.
Antiproliferative activity against human A549 non-MET-addicted cancer cells assessed as viability reduction incubated 72 hrs by CCK-8 assay.
|
42748863 |
| HCC827 | IC50 |
2.1 μM
|
Antiproliferative activity against human HCC827 non-MET-addicted cancer cells assessed as viability reduction incubated 72 hrs by CCK-8 assay.
Antiproliferative activity against human HCC827 non-MET-addicted cancer cells assessed as viability reduction incubated 72 hrs by CCK-8 assay.
|
42748863 |
| HCT-116 | IC50 |
1.8 μM
|
Antiproliferative activity against human HCT116 non-MET-addicted cancer cells assessed as viability reduction incubated 72 hrs by CCK-8 assay.
Antiproliferative activity against human HCT116 non-MET-addicted cancer cells assessed as viability reduction incubated 72 hrs by CCK-8 assay.
|
42748863 |
| T47D | IC50 |
3.5 μM
|
Antiproliferative activity against human T47D non-MET-addicted cancer cells assessed as viability reduction incubated 72 hrs by CCK-8 assay.
Antiproliferative activity against human T47D non-MET-addicted cancer cells assessed as viability reduction incubated 72 hrs by CCK-8 assay.
|
42748863 |
| KG-1 | IC50 |
5.2 μM
|
Antiproliferative activity against human KG-1 non-MET-addicted cancer cells assessed as viability reduction incubated 72 hrs by CCK-8 assay.
Antiproliferative activity against human KG-1 non-MET-addicted cancer cells assessed as viability reduction incubated 72 hrs by CCK-8 assay.
|
42748863 |
| Jurkat | IC50 |
4.0 μM
|
Antiproliferative activity against human Jurkat non-MET-addicted cancer cells assessed as viability reduction incubated 72 hrs by CCK-8 assay.
Antiproliferative activity against human Jurkat non-MET-addicted cancer cells assessed as viability reduction incubated 72 hrs by CCK-8 assay.
|
42748863 |
| THP-1 | IC50 |
>10 μM
|
Antiproliferative activity against human THP-1 non-MET-addicted cancer cells assessed as viability reduction with IC50 greater than 10 μM incubated 72 hrs by CCK-8 assay.
Antiproliferative activity against human THP-1 non-MET-addicted cancer cells assessed as viability reduction with IC50 greater than 10 μM incubated 72 hrs by CCK-8 assay.
|
42748863 |
In Vitro
c-Met-IN-32 inhibits c-Met kinase in a cell-free LanthaScreen binding assay with an IC50 of 18 nM[1].
c-Met-IN-32 (1 μM) exhibits a more refined kinome profile, with >80% inhibition restricted to MER, FYN, and SRC[1].
c-Met-IN-32 (10 μM) shows moderate Egg-PAMPA permeability, moderate to good liver microsomal stability, and weak inhibition of five major CYP450 isoforms[1].
c-Met-IN-32 (compound 41) (72 h) inhibits EBC-1 cell viability with an IC50 of 0.12 μM[1].
c-Met-IN-32 (0.1-10 μM; 2 h) blocks c-Met autophosphorylation and downstream AKT/ERK signaling in EBC-1 cells[1].
c-Met-IN-32 (2-10 nM; 48 h) inhibits EBC-1 cell migration in a concentration-dependent manner at nanomolar concentrations[1].
c-Met-IN-32 (2-10 nM; 24 h) inhibits EBC-1 cell migration and invasion at nanomolar concentrations[1].
c-Met-IN-32 (50-500 nM; 24 h) induces apoptosis in EBC-1 cells in a concentration-dependent manner[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:EBC-1 cells
-
Concentration:0.1, 0.3, 1, 3, and 10 μM
-
Incubation Time:2 h
-
Result:Produced a concentration-dependent decrease in phosphorylation of c-Met, AKT, and ERK.
p-MET was reduced at 0.1 μM and almost completely abolished at 1 μM and above; p-AKT and p-ERK were substantially suppressed at 0.3 μM.
-
Cell Line:EBC-1 cells
-
Concentration:50, 100, 200, and 500 nM
-
Incubation Time:24 h
-
Result:The apoptotic rate increased from 5.2% (DMSO control) to 9.3%, 15.4%, 20.1%, and 24.8% at 50, 100, 200, and 500 nM, respectively.
-
Cell Line:EBC-1 cells
-
Concentration:2, 5, and 10 nM
-
Incubation Time:0, 12, 24, and 48 h
-
Result:At 48 h, DMSO control achieved approximately 43% wound closure; compound 41 reduced wound closure to approximately 20% at 2 nM, 16% at 5 nM, and 12% at 10 nM.
Parmacokinetics
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c nude (male, 6-8 weeks old)[1]
-
Dosage:30 mg/kg
-
Administration:p.o.; once daily; 14 days
-
Result:Produced a tumor growth inhibition (TGI) rate of 82.2% over the 14-day period.
Chemical Information
-
분자량 646.68
-
화학식 C35H36F2N4O6
-
SMILES
COC1=CC2=C(N=CC=C2OC3=CC=C(NC(C4(CCC4)NC(C5=CC=C(F)C=C5)=O)=O)C=C3F)C=C1OCCCN6CCOCC6
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocol
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Cell migration
Cell migration is a method that plays an important role in wound healing, cell differentiation, embryonic development, etc.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Cell invasion
Cell invasion is the ability of cells to migrate from one area to another via the extracellular matrix. Cell invasion is the response of normal and cancer cells to chemical and mechanical stimuli. Before migrating to a new region, the extracellular matrix is degraded by proteases within the cell. Cell invasion often occurs during wound repair, vascularization and inflammation, abnormal tissue invasion, and tumor cell metastasis.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
순도&문서
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)